2025-04-22 - Analysis Report
## Recursion Pharmaceuticals Inc. (RXRX) Stock Analysis

**0) Key Figures Overview:**

RXRX, Recursion Pharmaceuticals Inc., is a biotechnology company focused on drug discovery.  The company is currently significantly underperforming the S&P 500.

**1) Performance Comparison & Alpha/Beta Analysis:**

* **Cumulative Return (RXRX):** -50.42%
* **Cumulative Return (VOO):** 9.75%
* **Return Difference:** -60.17% (RXRX underperformed VOO by 60.17%)
* **Relative Divergence:** 12.9% (This means RXRX's underperformance is in the lower 13th percentile relative to its historical range of underperformance against the VOO.)


The provided Alpha/Beta analysis shows consistently negative Alpha values and high Beta values across the given periods, indicating significant underperformance relative to the market (high Beta signifies high volatility and correlation with the market) and a failure to generate excess returns (negative Alpha).  The high Maximum Drawdown (MDD) further highlights the significant risk associated with this investment.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | 5.0% | 73.6% | -12.0% | 4.0 |
| 2022-2024  | 0.0% | 73.6% | -22.0% | 2.8 |
| 2023-2025  | 1.0% | 73.6% | -8.0% | 2.2 |


**2) Recent Price Movement:**

* **Closing Price:** $5.41
* **Previous Close:** $5.50
* **Daily Change:** -1.64%
* **5-Day Moving Average:** $5.48
* **20-Day Moving Average:** $5.32
* **60-Day Moving Average:** $6.81

The price is currently below all three moving averages, suggesting a bearish trend.  The 60-day moving average is considerably higher, indicating a significant price decline over the past two months.

**3) Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.4082 (Medium Risk)
* **RSI:** 51.26 (Slightly above neutral; neither overbought nor oversold)
* **PPO:** 2.43 (Positive, suggesting bullish momentum, but needs context of historical data)
* **20-Day Relative Divergence Change:** +2.3 (Short-term upward trend)
* **Expected Return:** -241.8% (This extremely negative expected return relative to the S&P 500 indicates significant underperformance is expected to persist if current trends continue over the long term.)
* **Price Change:** The -1.64% daily change suggests a minor downward movement, not a drastic drop.

**4) Recent Earnings Analysis:**

The company has consistently reported negative EPS and relatively low revenue across the provided quarters.  This highlights a concerning lack of profitability.


| 날짜 | EPS | 매출 |
|---|---|---|
| 2024-11-06 | -0.34 | 0.03 B$ |
| 2024-08-08 | -0.4 | 0.01 B$ |
| 2024-05-09 | -0.39 | 0.01 B$ |
| 2023-11-09 | -0.43 | 0.01 B$ |
| 2024-11-06 | -0.43 | 0.01 B$ |


**5) Financial Information:**

The financial information confirms the lack of profitability.  Negative profit margins and a declining Return on Equity (ROE) are significant red flags.  While revenue increased slightly in Q3 2024, it is still very low and not sustainable given the large negative profit margin.

Revenue and Profitability:

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $0.00B | -183.62% |
| 2024-09-30 | $0.03B | 53.69% |
| 2024-06-30 | $0.01B | 36.14% |
| 2024-03-31 | $0.01B | 17.23% |
| 2023-12-31 | $0.01B | 6.99% |

Capital and Profitability:

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $1.03B | -17.29% |
| 2024-09-30 | $0.52B | -18.27% |
| 2024-06-30 | $0.58B | -16.69% |
| 2024-03-31 | $0.40B | -22.78% |
| 2023-12-31 | $0.46B | -20.07% |


**6) Overall Conclusion:**

Recursion Pharmaceuticals (RXRX) exhibits significant underperformance compared to the S&P 500, with consistently negative Alpha, high Beta, and substantial maximum drawdown.  Negative earnings, low revenue, and negative profit margins paint a bleak picture of the company's financial health. While some short-term technical indicators hint at a potential upward trend, the fundamental weaknesses are severe.  The extremely negative projected long-term return reinforces the considerable risk involved.  Investing in RXRX carries substantial risk and is not recommended without a thorough understanding of the company's prospects for a significant turnaround.  Further in-depth due diligence is crucial before considering any investment.
